Conversely, the pharmacological blockade of Orai1 with carboxyamidotriazole, which targets both vascular endothelial cells [73] and tumor-derived ECFC [290], has been probed in phase I-III clinical trials launched towards several malignancies [304,312]. The gene discussed is ORAI1; the disease is neoplasm.